



Investor Presentation



ASX: IIQ | 27 October 2022



This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company’s activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision and does not contain all information about the Company’s assets and liabilities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to the Company’s securities necessary to make an investment decision. The information in this presentation should be read in conjunction with the Company’s other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), available at www.asx.com.au. The information in this presentation is based on the Company’s own information and estimates and has not been independently verified. The Company is not responsible for providing updated information and assumes no responsibility to do so. Any investment in the Company should be considered speculative and there is no guarantee that they will make a return on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the future.

This Presentation may contain certain “forward-looking statements” that are based on management’s beliefs, assumptions and expectations and on information currently available to management. The words “expect”, “anticipate”, “estimate”, “intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including INOVIQ or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.

Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company’s prospects.

You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company’s views on its future financial performance or condition. Past performance, including past share price performance, of INOVIQ cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance.



- Developing next-generation exosome capture tools and precision diagnostics for cancer and other diseases
- Proprietary technology platforms for biomarker isolation and detection
- Products in-market for exosome research & bladder cancer
- Multi-product pipeline for detection and monitoring of breast, ovarian and other cancers targeting \$15B global markets
- Compelling early data in breast and ovarian cancers
- Multiple key inflection points over next 12 months
- Strong cash position of \$15.4m to fund operations and pipeline development

Financial information (ASX:IIQ)

Ordinary shares	92,018,702
Share price (26/10/22)	A\$0.550
Market capitalisation (26/10/22)	A\$50.6m
Cash position (30/6/22)	A\$15.4m
Ave monthly cash burn (Q4 FY22)	A\$561k
Top 20 Shareholders (26/10/22)	34.8%

Share price performance




Products and pipeline



PRODUCT	INDICATION	PLATFORM	USE	RESEARCH	ASSAY DEVELOPMENT	CLINICAL DEVELOPMENT	REGISTRATION
hTERT ¹	Bladder Cancer	ICC	Adjunct to cytology				★ In-market
EXO-NET-RUO	Exosome Capture	Device	Research tool				★ In-market
Exosome-OC ² (OCR-7)	Ovarian Cancer	Multioomic	Screening				
SubB2M-BCM	Breast Cancer	Immunoassay	Monitoring				2023
SubB2M-OCM	Ovarian Cancer	Immunoassay	Monitoring				2023
SubB2M-SPR	Multi-cancer	SPR	Risk assessment				
SubB2M-PCS	Prostate Cancer	Immunoassay	Detection				
SubB2M-PaC	Pancreatic Cancer	Immunoassay	Detection				
BARD1-Ovarian ³	Ovarian Cancer	Immunoassay	Detection				
BARD1-Breast ³	Breast Cancer	Immunoassay	Detection				
BARD1-Lung ³	Lung Cancer	Immunoassay	Detection				



- SubB2M detects the pan-cancer biomarker, Neu5Gc, found at elevated levels in multiple human cancers¹
- Applications for detection and monitoring of multiple cancers (breast, ovarian, prostate, pancreatic, melanoma, and others)
- SubB2M cGMP contract manufactured³
- INOVIQ is progressing two approaches:
 - SubB2M-based **SPR** test for detection of Neu5Gc for **cancer risk assessment**
 - SubB2M-based **immunoassays** for detection of Neu5Gc decorated cancer antigens (CA125 and CA15.3) for **cancer monitoring**






- POC data in case-control studies showed the SubB2M-based SPR test detected:
 - Ovarian Cancer at 100% sensitivity and 100% specificity across all stages (n = 69) ^{1,2}
 - Breast Cancer at 95% sensitivity and 100% specificity across all stages (n = 118) ^{1,2,3}
- Agreement with Nicoya to transfer, develop and evaluate SubB2M-based SPR test on next-gen Alto digital SPR instrument⁴
- In development for:
 - **Cancer risk assessment** in conjunction with approved screening tests
 - Potential for further development as a **multi-cancer detection test**




Breast Cancer data

SENSITIVITY BY STAGE at 10.5 GPU cutoff¹
n=118 (96 cancers : 22 controls)



Ovarian Cancer data

SENSITIVITY BY STAGE at specified cutoffs
n=69 (47 cancers : 22 controls)





- Initial assay design, prototype development and feasibility testing of SubB2M immunoassays by Griffith University³
- Agreement with ResearchDx (US-based contract diagnostics organization) to further develop and validate SubB2M-based immunoassays¹
- SubB2M-based immunoassay development, optimisation and analytical validation underway³
- On-track to commence clinical testing by Dec-22
- SubB2M-based immunoassays detect Neu5Gc-decorated single cancer antigens:
 - SubB2M/CA15.3 test for monitoring breast cancer
 - SubB2M/CA125 test for monitoring ovarian cancer
- Simple, cost-effective tests to improve the accuracy of existing standard of care tests





FIGURE: ResearchDx data shows SubB2M-CA15.3 assay measures from 5 - 250 U/ml. Limit of Quantitation 5 U/ml and CV 7.8%.



● SubB2M-CA15.3
 ● SubB2M-CA125
 ● SubB2M SPR
 Assay classification and performance will be confirmed in retrospective clinical studies



- **EXO-NET pan-exosome capture** is a 'research use only' (RUO) product for isolation of exosomes from body fluids with speed, purity and yield advantages
- Enables **rapid, efficient and scalable isolation** of enriched exosomes
- US contract sales force in place to **accelerate commercial roll-out**
- **Commercialisation** strategy to embed EXO-NET into the discovery, research & development phases of future exosome-based diagnostics & therapeutics
- Expanding **EXO-NET pipeline** for new product opportunities
- **Collaborating** with KOLs to validate EXO-NET for cancer, inflammatory, metabolic and neurodegenerative diseases
- **Manufacturing** moving to automated cGMP production



GLOBAL MARKET OPPORTUNITY FOR
EXOSOME RESEARCH MARKET

US\$661 million



Collaboration with UQ to develop world-first exosome-based ovarian cancer screening test¹

- **EXO-NET technology** used for fast and accurate and scalable exosome isolation
- UQ's OCRF-7 validated in an retrospective case-control study achieving over **90% accuracy** for detection of stage I / II ovarian cancer³
- UQ project funded via a \$2.7m MRFF² grant
- INOVIQ has the **exclusive option to license** the development and commercialisation rights
- Meets **critical need** for early detection of ovarian cancer to improve women's health outcomes and help save lives




FIGURE: Retrospective case (n = 153) : control (n = 312) study comparing accuracy of OCRF-7 algorithm to CA-125 assay



4Q CY2022

- ✓ Agreement with Nicoya to transfer, develop & evaluate SubB2M SPR test
- Commence SubB2M clinical studies for BC
- Commence SubB2M clinical studies for OC
- Progress development of new EXO-NET capture products
- Progress on UQ collaboration for exosome OC test
- New EXO-NET collaborations

CY2023

- SubB2M BC test results
- SubB2M OC test results
- Secure LDT laboratory partner
- SubB2M analytical validation
- SubB2M clinical validation
- Launch SubB2M BC test (LDT)
- Launch SubB2M OC test (LDT)
- Secure partnering agreements for EXO-NET
- Progress results on exosome OC test
- Establish EXO-NET manufacture at Melbourne
- EXO-NET publication/s



**Innovative
Company**

**Patented
Technology**

**Strong
Pipeline**

**Compelling
Results**

**Commercialised
Products**

**Significant growth
Potential**

**Experienced
Leadership**

**Strong cash
Position**

INOVIQ Ltd

23 Normanby Road
Notting Hill VIC 3168
Australia

p. +61 3 9548 7586

e. info@inoviq.com

w. www.inoviq.com

Dr Learne Hinch

Chief Executive Officer

e. lhinch@inoviq.com

m. +61 400 414 416